Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion

Onconetix, Inc.

Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.
PRIME multi-center clinical study initiated with Labcorp; first participants enrolled, targeting up to 500 men for U.S. validation.
European commercial expansion: ~100 Proclarix tests performed in UK screening initiative in Q1 2026; collaboration partner identified in Turkey.
Proclarix is a CE-IVD certified blood test for identifying clinically significant prostate cancer, designed to reduce overdiagnosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.